Long term proton pump Inhibitor (PPI) use and incidence of gastric (pre) malignant lesions

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Nasseri Moghaddam, Siavosh ^a   Islami, L ^b   Kalantarian, S ^b   Malekzadeh, R ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADENOMA; ATROPHIC GASTRITIS; BACTERIAL INFECTION; CANCER INCIDENCE; CARCINOID; COMPARATIVE STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPLASIA; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INCIDENCE; INTESTINE METAPLASIA; LONG TERM CARE; OUTCOME ASSESSMENT; PEPTIC ULCER; QUALITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; STOMACH TUMOR; TREATMENT DURATION;

EID: 44949151784     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007098     Document Type: Review

References (29)

1. Agrawal 2000 Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs. ranitidine in healing non-steroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Archives of Internal Medicine 2000;160(10):1455-61.
2. Chiba 1997 Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112(6):1798-810.
3. Correa 1988 Correa P. A human model of gastric carcinogenesis. Cancer Research 1988;48(13):3554-60.
4. Dajani 2000 Dajani EZ. Gastroesophageal reflux disease: pathophysiology and pharmacology overview. Journal of the Association for Academic Minority Physicians 2000;11(1):7-11.
5. Dekkers 1999 Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Alimentary Pharmacology & Therapeutics 1999;13(2):179-86.
6. Freston 1994 Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Annals of Internal Medicine 1994;121(3):232-3.
7. Haag 2003 Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy 2003;35(2):112-7.
8. Hetzel 1988 Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al.Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95(4):903-12.
9. Higgins 2006a Higgins JPT, Green S, editors Appendix 5b. Formulating the problem. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. http://www.cochrane.org/resources/ handbook/hbook.htm (accessed 6th October 2006).
10. Higgins 2006b Higgins J, Green S, editors Section 6. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6. http://www.cochrane.org/resources/handbook/hbook.htm (accessed 6th October 2006).
11. Holt 1991 Holt S, Howden CW. Omeprazole: Overview and opinion. Digestive Diseases and Sciences 1991;36(4):385-93.
12. Kader 1998 Kader SA, Mansour AM, Mohran Z, el-Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. Journal of the Egyptian Society of Parasitology 1998;28(1):149-57.
13. Klinkenberg 2000 Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al.Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118(4):661-9.
14. Koop 1990 Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Alimentary Pharmacology & Therapeutics 1990;4(2):131-8.
15. Kuipers 1996 Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al.Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. The New England Journal of Medicine 1996;334(16):1018-22.
16. Laheij 2004 Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292(16):1955-60.
17. Lloyd-Davies 1988 Lloyd-Davies KA, Rutgersson K, Solvell L. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Alimentary Pharmacology & Therapeutics 1988;2(1):13-32.
18. Lundell 1999 Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al.Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999;117(2): 319-26.
19. Marks 1994 Marks RD, Richter JE, Rizzo J. Omeprazole vs. H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106(4):907-15.
20. Maton 1989 Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, et al.Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 1989;97(4):827-36.
21. Moayyedi 2000 Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al.Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5(4):206-14.
22. Neal 1996 Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996;312(7028):414-5.
23. Norton 1999 Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al.Surgery to cure the Zollinger-Ellison syndrome. The New England Journal of Medicine 1999;341(9):635-44.
24. Poynard 1995 Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. European Journal of Gastroenterology & Hepatology 1995;7(7):661-5.
25. Reynaert 1995 Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association?. Journal of Gastroenterology 1995;30(6):775-8.
26. Sanduleanu 1999 Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al.Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Alimentary Pharmacology & Therapeutics 1999;13(2):145-53.
27. Schenk 2000 Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, et al.Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46(5):615-21.
28. Vigneri 1995 Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al.A comparison of five maintenance therapies for reflux esophagitis. The New England Journal of Medicine 1995;333(17):1106-10.
29. Wolfe 2000 Wolfe MM, Sachs G. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118(2 Suppl 1):S9-31.